Evidence map›Paper›PMID 36428506›Full record

ArticleBiomedicines2022

Non-Criteria Obstetric Antiphospholipid Syndrome: How Different Is from Sidney Criteria? A Single-Center Study.

Víctor M Martínez-Taboada, Pedro Blanco-Olavarri, Sara Del Barrio-Longarela, Leyre Riancho-Zarrabeitia, Ana Merino, Alejandra Comins-Boo, Marcos López-Hoyos, José L Hernández

Open access · goldAbstract read
In one paragraph

Article in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Víctor M Martínez-TaboadaDivision of Rheumatology, Hospital Universitario Marqués de Valdecilla-IDIVAL, 39008 Santander, Spain.
Pedro Blanco-OlavarriDivision of Rheumatology, Hospital Universitario Marqués de Valdecilla-IDIVAL, 39008 Santander, Spain.
Sara Del Barrio-LongarelaDivision of Obstetrics and Gynecology, Hospital Marqués de Valdecilla, 39008 Santander, Spain.
Leyre Riancho-ZarrabeitiaRheumatology Department, Hospital Sierrallana-IDIVAL, 39300 Torrelavega, Spain.
Ana MerinoDivision of Obstetrics and Gynecology, Hospital Marqués de Valdecilla, 39008 Santander, Spain.
Alejandra Comins-BooImmunology Department, Hospital Universitario Marqués de Valdecilla-IDIVAL, 39008 Santander, Spain.ORCID 0000-0001-8353-6211
Marcos López-HoyosImmunology Department, Hospital Universitario Marqués de Valdecilla-IDIVAL, 39008 Santander, Spain.ORCID 0000-0003-0562-427X
José L HernándezDepartamento de Medicina y Psiquiatría, Universidad de Cantabria, 39011 Santander, Spain.ORCID 0000-0002-6585-8847
Universidad de Cantabria · ESInstituto de Investigación Marqués de Valdecilla · ESMarqués de Valdecilla University Hospital · ESHospital Sierrallana · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aims to compare the demographic characteristics, clinical features, serology, and fetal-maternal outcomes between women with obstetric antiphospholipid syndrome (APS) and those with non-criteria (NC)-APS and seronegative (SN)-APS. Two-hundred and sixty-three women with APS obstetric morbidity ever pregnant were included. Of those, 66 met the APS classification criteria, 140 were NC-APS, and 57 were SN-APS. Patients with other autoimmune diseases were excluded. Adverse pregnancy outcomes (APO) included early pregnancy loss, fetal death, preeclampsia, abruptio placentae, and preterm birth. The mean age of the study group was 33.6 ± 5.3 years, and patients were followed up for 129.5 ± 81.9 months. In the NC-APS group, 31 (22.1%) did not fulfill clinical and serological criteria (Subgroup A), 49 (35%) did meet clinical but not serologic criteria (Subgroup B), and 60 (42.9%) fulfilled the serologic criteria but not the clinical ones (Subgroup C). The cardiovascular risk burden was higher in the APS group, due to a higher proportion of smoking. Patients with criteria APS received more intensive treatment than patients in the other study groups. The addition of standard of care (SoC) treatment significantly improved live birth and decreased APO in all groups. Significant clinical differences were observed between the study groups. However, when treated with SoC, fetal-maternal outcomes were similar, with a significant improvement in live births and a decrease in APO. Risk stratification in patients with obstetric morbidity associated with APS can help individualize their treatment.

Indexed as

antiphospholipid antibodiesantiphospholipid syndromefetal lossnon-criteriaobstetric morbiditypregnancy

Identifiers

PMID36428506
PMCPMC9687766
OpenAlexW4309311722

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.